Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
INOVIO (NASDAQ:INO) announced that it will present immunological activity data for INO-3107 at the American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology conference, scheduled for February 23-26, 2025. The poster presentation will focus on the loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following INO-3107 treatment, specifically highlighting the induction of emergent T cells in patients who showed durable complete clinical response. The abstract will be made available on INOVIO's website after the conference.
INOVIO (NASDAQ:INO) ha annunciato che presenterà dati sull'attività immunologica per INO-3107 alla conferenza della American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology, in programma dal 23 al 26 febbraio 2025. La presentazione del poster si concentrerà sulla perdita di HPV-6 rilevabile nei pazienti con Papillomatosi Respiratoria Ricorrente dopo trattamento con INO-3107, evidenziando in particolare l'induzione di cellule T emergenti nei pazienti che hanno mostrato una risposta clinica completa e duratura. Il riassunto sarà reso disponibile sul sito web di INOVIO dopo la conferenza.
INOVIO (NASDAQ:INO) anunció que presentará datos sobre la actividad inmunológica de INO-3107 en la conferencia de la Asociación Americana para la Investigación del Cáncer – Descubrimiento e Innovación en Inmuno-Oncología, programada para el 23-26 de febrero de 2025. La presentación del cartel se centrará en la pérdida de HPV-6 detectable en pacientes con Papilomatosis Respiratoria Recurrente tras el tratamiento con INO-3107, destacando específicamente la inducción de células T emergentes en pacientes que mostraron una respuesta clínica completa y duradera. El resumen estará disponible en el sitio web de INOVIO después de la conferencia.
INOVIO (NASDAQ:INO)는 2025년 2월 23일부터 26일 사이에 열리는 미국암연구협회 – 면역온콜로지 발견 및 암 면역학 혁신 컨퍼런스에서 INO-3107에 대한 면역학적 활동 데이터를 발표할 것이라고 발표했습니다. 포스터 발표는 INO-3107 치료 후 재발성 호흡기 유두종 환자에서 검출 가능한 HPV-6의 손실에 초점을 맞추며, 특히 지속적인 완전 임상 반응을 보인 환자에서 발생하는 T 세포의 유도를 강조합니다. 초록은 컨퍼런스 이후 INOVIO의 웹사이트에서 제공될 예정입니다.
INOVIO (NASDAQ:INO) a annoncé qu'il présentera des données sur l'activité immunologique de INO-3107 lors de la conférence de l'American Association for Cancer Research – Découverte et innovation en immuno-oncologie, prévue du 23 au 26 février 2025. La présentation de l'affiche se concentrera sur la perte de HPV-6 détectable chez les patients atteints de papillomatose respiratoire récurrente après traitement par INO-3107, en mettant en évidence l'induction de cellules T émergentes chez les patients ayant montré une réponse clinique complète et durable. Le résumé sera disponible sur le site Web d'INOVIO après la conférence.
INOVIO (NASDAQ:INO) kündigte an, dass es auf der Konferenz der American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology, die vom 23. bis 26. Februar 2025 stattfinden wird, Daten zur immunologischen Aktivität von INO-3107 präsentieren wird. Die Posterpräsentation wird sich auf den Verlust von nachweisbarem HPV-6 bei Patienten mit wiederkehrender respiratorischer Papillomatose nach Behandlung mit INO-3107 konzentrieren und dabei insbesondere die Induktion aufkommender T-Zellen bei Patienten hervorheben, die eine langanhaltende vollständige klinische Antwort gezeigt haben. Die Zusammenfassung wird nach der Konferenz auf der Website von INOVIO verfügbar sein.
- Clinical data shows complete response in RRP patients treated with INO-3107
- Evidence of HPV-6 elimination in treated patients
- Successful T cell induction demonstrated by the treatment
- None.
Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107
American Association for Cancer Research – Immuno-Oncology
Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025)
Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107"
The abstract will be made available on INOVIO's website following the conference.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immune-response-data-for-ino-3107-to-be-presented-as-a-poster-at-american-association-for-cancer-research-immuno-oncology-aacr-io-conference-302372309.html
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
What are the key findings of INO-3107 treatment in RRP patients presented at AACR-IO 2025?
When will INOVIO present the INO-3107 immunological data at AACR-IO conference?
What is the significance of HPV-6 elimination in INO-3107 treated patients?
How can investors access the INO-3107 abstract presented at AACR-IO 2025?
